Limits...
Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes.

He G, Wang C, Li Q, Tan H, Chen F, Huang Z, Yu B, Zheng L, Zheng R, Liu D - Cancer Cell Int. (2014)

Bottom Line: The PML/RARα fusion gene was present in six patients and two patients presented a mixed PML/RARα and AML1/ETO genotype.Five cases achieved CR and two cases did not achieve remission and one case transform into AML-M2 after CR1.The clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the present study, providing information on the FAB sub-classification.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Haizhu District, 510000 Guangzhou, China.

ABSTRACT

Background: There is limited information on a special subtype of Acute myeloid leukemia (AML) characterized by >20% myeloblasts and >20% abnormal promyelocytes in bone marrow and peripheral blood.

Objective: The objective of the present investigation was to explore the clinical and laboratory features of seven patients with AML-M2/M3.

Method: We retrospectively assessed cell morphology, cytochemistry, immunophenotype, cytogenetics, and clinical features of seven patients with this rare subtype of AML.

Results: All seven cases had thrombocytopenia, coagulation abnormalities, >20% myeloblasts and abnormal promyelocytes. The PML/RARα fusion gene was present in six patients and two patients presented a mixed PML/RARα and AML1/ETO genotype. Five cases achieved CR and two cases did not achieve remission and one case transform into AML-M2 after CR1.

Conclusions: The clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the present study, providing information on the FAB sub-classification.

No MeSH data available.


Related in: MedlinePlus

FCM of AML-M2/M3 patients. M-Q: Immunophenotype of Case 2 as measured by FCM. R-W: Immunophenotype of Case 3. X: Immunophenotype of Case 5. Bone marrow karyocytes contained a group of abnormal cells (group C, red) accounting for 76.4% of the total.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325959&req=5

Fig2: FCM of AML-M2/M3 patients. M-Q: Immunophenotype of Case 2 as measured by FCM. R-W: Immunophenotype of Case 3. X: Immunophenotype of Case 5. Bone marrow karyocytes contained a group of abnormal cells (group C, red) accounting for 76.4% of the total.

Mentions: Bone marrow smears revealed 42.5% myeloblasts and 30% abnormal promyelocytes. Cytochemistry indicated 99% MPO (+) cells. Most cells also appeared AS-DCE (+). The immunophenotype was MPO (+), CD117 (+), LCA (+), about 20% Ki-67(+), CD3 (-), CD34 (-), TdT (-), CK (-), Ag (++), and Fe (-). Cytogenetic analysis indicated the presence of the PML/RARа fusion gene, S type. Immunophenotyping by FCM revealed that 76.4% of BM karyocytes were abnormal (group C, red). Most cells were weakly CD45 (+), while 30.9% were CD13 (+) 11.6% CD15 (+), 95.5% CD33 (+), 96.5% CD56 (+), 16.9% CD64 (+), 78.4% CD117 (+), and 84.3% were positive for the cytoplasmic antigen of cMPO. Cells were negative for antigens of the lymphocytic lineage (Figure 2).Figure 2


Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes.

He G, Wang C, Li Q, Tan H, Chen F, Huang Z, Yu B, Zheng L, Zheng R, Liu D - Cancer Cell Int. (2014)

FCM of AML-M2/M3 patients. M-Q: Immunophenotype of Case 2 as measured by FCM. R-W: Immunophenotype of Case 3. X: Immunophenotype of Case 5. Bone marrow karyocytes contained a group of abnormal cells (group C, red) accounting for 76.4% of the total.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325959&req=5

Fig2: FCM of AML-M2/M3 patients. M-Q: Immunophenotype of Case 2 as measured by FCM. R-W: Immunophenotype of Case 3. X: Immunophenotype of Case 5. Bone marrow karyocytes contained a group of abnormal cells (group C, red) accounting for 76.4% of the total.
Mentions: Bone marrow smears revealed 42.5% myeloblasts and 30% abnormal promyelocytes. Cytochemistry indicated 99% MPO (+) cells. Most cells also appeared AS-DCE (+). The immunophenotype was MPO (+), CD117 (+), LCA (+), about 20% Ki-67(+), CD3 (-), CD34 (-), TdT (-), CK (-), Ag (++), and Fe (-). Cytogenetic analysis indicated the presence of the PML/RARа fusion gene, S type. Immunophenotyping by FCM revealed that 76.4% of BM karyocytes were abnormal (group C, red). Most cells were weakly CD45 (+), while 30.9% were CD13 (+) 11.6% CD15 (+), 95.5% CD33 (+), 96.5% CD56 (+), 16.9% CD64 (+), 78.4% CD117 (+), and 84.3% were positive for the cytoplasmic antigen of cMPO. Cells were negative for antigens of the lymphocytic lineage (Figure 2).Figure 2

Bottom Line: The PML/RARα fusion gene was present in six patients and two patients presented a mixed PML/RARα and AML1/ETO genotype.Five cases achieved CR and two cases did not achieve remission and one case transform into AML-M2 after CR1.The clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the present study, providing information on the FAB sub-classification.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Haizhu District, 510000 Guangzhou, China.

ABSTRACT

Background: There is limited information on a special subtype of Acute myeloid leukemia (AML) characterized by >20% myeloblasts and >20% abnormal promyelocytes in bone marrow and peripheral blood.

Objective: The objective of the present investigation was to explore the clinical and laboratory features of seven patients with AML-M2/M3.

Method: We retrospectively assessed cell morphology, cytochemistry, immunophenotype, cytogenetics, and clinical features of seven patients with this rare subtype of AML.

Results: All seven cases had thrombocytopenia, coagulation abnormalities, >20% myeloblasts and abnormal promyelocytes. The PML/RARα fusion gene was present in six patients and two patients presented a mixed PML/RARα and AML1/ETO genotype. Five cases achieved CR and two cases did not achieve remission and one case transform into AML-M2 after CR1.

Conclusions: The clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the present study, providing information on the FAB sub-classification.

No MeSH data available.


Related in: MedlinePlus